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Abstract

Author Manuscript

Objectives—To assess whether late surfactant treatment of extremely low gestational age
newborn (ELGAN) infants requiring ventilation at 7–14 days, who often have surfactant
deficiency and dysfunction, safely improves survival without bronchopulmonary dysplasia (BPD).
Study design—ELGAN infants (≤ 28 0/7 weeks) who required mechanical ventilation at 7–14
days were enrolled in a randomized, masked controlled trial at 25 US centers. All infants received
inhaled nitric oxide (INO) and either surfactant (calfactant/Infasurf®) or sham instillation every 1–
3 days to a maximum of 5 doses while intubated. The primary outcome was survival at 36 weeks
postmenstrual age (PMA) without BPD, evaluated by physiologic oxygen/flow reduction.

Author Manuscript

Results—Between January 2010 and September 2013, 511 infants were enrolled. There were no
differences between treatment groups in mean birth weight (701±164 g), gestational age (25.2±1.2
weeks), percentage <26 weeks (70.6%), race, sex, severity of lung disease at enrollment, or comorbidities of prematurity. Survival without BPD was not different between treated vs. controls at
36 weeks PMA (31.3% vs. 31.7%; relative benefit 0.98 (95% CI: 0.75, 1.28 p=0.89) or 40 weeks
(58.7% vs. 54.1%; relative benefit 1.08:0.92, 1.27 p=0.33). There were no differences between
groups in serious adverse events, co-morbidities of prematurity, nor in the severity of lung disease
to 36 weeks.
Conclusions—Late treatment with up to 5 doses of surfactant in ventilated premature infants
receiving iNO was well tolerated but did not improve survival without BPD at 36 or 40 weeks.
Pulmonary and neurodevelopmental assessments are ongoing.

Author Manuscript

Bronchopulmonary dysplasia (BPD), initially described by Northway in 1967(1), is the most
common form of chronic lung disease in children with an estimated 15,000 new cases
annually in the United States. This condition affects infants born prematurely, is a major
contributor to the $22 billion cost of prematurity each year, and is associated with long-term
pulmonary disability, neurodevelopmental abnormalities and death. (2–4) With increased
survival of extremely low gestational age infants (ELGANs, ≤28 wk gestation), another
form of BPD has emerged that is characterized by impaired alveolar and microvascular
development with excess tone and reactivity of airway smooth muscle. (5–10)
Despite antenatal glucocorticoid treatment to enhance lung maturation and replacement
surfactant treatment at birth, as well as the more aggressive use of nasal continuous positive
airway pressure (NCPAP) and nasal intermittent positive pressure ventilation (NIPPV),
premature infants often need prolonged intubation and mechanical ventilation support and/or
supplemental oxygen. When mechanical ventilation support is required beyond 7 days of
J Pediatr. Author manuscript; available in PMC 2017 January 01.
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age, BPD occurs in more than 70% of surviving ELGANS.(11, 12) Factors contributing to
BPD include structurally immature lungs, a compliant chest wall, deficiency and
dysfunction of pulmonary surfactant, oxidant stress, immature respiratory drive, perturbed
intrauterine environment, exposure to infection and inflammation and genetic susceptibility.
Most of these infants experience clinical episodes of increased requirement for ventilatory
support that are associated with dysfunctional surfactant, which is primarily due to low
surfactant protein B (SP-B).(13) We and others have reported results from small studies of
late surfactant treatment in premature infants who required ventilatory support beyond one
week of life.(14–19) Surfactant treatment was well tolerated, with short-term improvement in
Respiratory Severity Score (RSS=mean airway pressure x FiO2) and SP-B content. (18, 19)
However, in these pilot studies of late surfactant alone, there was no improvement in
survival without BPD at 36 wk.

Author Manuscript

These observations provided the rationale for a large clinical trial of later doses of surfactant
(TOLSURF) to prevent episodes of respiratory decompensation and BPD. In our prior study
(NO CLD), a 25-day course of inhaled nitric oxide (iNO) started between 7 and 14 days of
age at 20 ppm significantly improved survival without BPD at 36 and 40 wk as well as
respiratory status to the age of 1 y (11, 20, 21). iNO did not improve long term surfactant
function(22) or markers of pulmonary inflammation and oxidative stress.(23, 24) For this
multifactorial disorder, it is likely that a combination of treatments directed at different
aspects of the pathogenesis will be needed to improve outcome. To address this question, we
conducted a randomized trial of late surfactant vs. placebo sham procedure in premature
infants receiving iNO.

METHODS
Author Manuscript

The Trial Of Late SURFactant (TOLSURF) was a masked, randomized, sham-controlled
trial conducted in 25 US hospitals (ClinicalTrials.gov: NCT01022580). The study was
designed to assess the effect of late doses of surfactant on BPD at 36 wk PMA in ELGANs
(≤ 28 0/7wk) who required intubation and mechanical ventilation between 7 and 14 days of
age and were receiving iNO. Infants were excluded if they had life threatening congenital
abnormalities, were clinically unstable, had bilateral grade 4 IVH or were unlikely to be
available for long-term pulmonary and neurodevelopmental follow-up.

Author Manuscript

The trial was conducted under the regulatory oversight of the FDA. IND # 79,367 for the
combined use of calfactant with iNO, is held by the PI (RAB). The research protocol was
approved by the IRBs of the participating institutions, and all parents signed a written
informed consent. The consent included “opt-in/opt-out” permission for long-term banking
of biospecimens and DNA. The consent was revised and reapproved by the DSMB and the
IRBs after the NIH Consensus Conference on the use of iNO in preterm infants.(25) The
NHLBI-appointed DSMB approved the protocol, informally reviewed safety data after every
60–80 infants were enrolled, and conducted two interim efficacy/futility analyses when both
36 and 40 week fully cleaned outcome information was available on 25% and 50% of the
recruitment expectation of 524. The second futility analysis (conducted with complete
outcome data for 301 infants [57% of 524]) was presented to the DSMB in August 2013,
and at that time the DSMB recommended to NHLBI that the study be terminated, stating
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that “based on a determination that the study treatment is very unlikely to demonstrate
efficacy, the DSMB decided that continuation of study treatment intervention could no
longer be justified” At the time of termination, although 511 of the planned 524 infants had
been randomized, there were more than 200 for whom complete cleaned outcome data to 40
wk were not yet available.

Author Manuscript
Author Manuscript

For this trial we selected calfactant (Infasurf® ONY INC), a natural surfactant extracted
from bovine lung lavage fluid, which has consistent amounts of SP-B (0.9% phospholipid)
and SP-C (1.5% phospholipid). Standard clinical doses of calfactant were administered to
treated infants by research staff behind a screen if the infants remained intubated (up to
maximum of 5 doses). Control infants received a sham procedure (no intervention) behind
the screen. Monitor and ventilator alarms were turned off during dosing to avoid unblinding
of clinical staff. To accommodate research staff availability and infant instability, the dosing
interval was not strictly set but could be repeated every 24 – 72 h up to 5 doses if the infant
still required intubation. Dosing could be discontinued by physician request or parental
withdrawal from the study. Clinical guidelines (Appendix 2; available at www.jpeds.com)
for management of ventilation, including re-intubation, blood pressure management, and use
of caffeine and postnatal corticosteroids were developed, presented at each clinical site and
agreed to by investigators. All infants received iNO (Ikaria INC) according to the protocol
used in the NOCLD trial.(11, 20) Although iNO therapy was accepted practice in the units
participating in the trial, there was concern about the potential cost for families in light of
the NIH Consensus Conference statement(25), and therefore the gas was provided at no
charge by Ikaria INC (Hampton, NJ) to infants participating in the study. Blinding by
treatment group is being maintained throughout the pulmonary and neurodevelopmental
follow-up to age 2 years. Tracheal aspirate (TA) samples were collected prior to each dose
of surfactant for analysis of surfactant and SP-B levels and later DNA isolation, and urine
samples were collected at regular intervals for examination of NO metabolites. The content
of SP-B in the large aggregate surfactant fraction was determined in baseline TA samples
from a subpopulation of infants using published methodology (19) in order to assess whether
enrolled infants had surfactant dysfunction and results will be published separately.

Author Manuscript

Patients were randomized to one of two groups: (1) sham instillation or (2) calfactant.
Randomized permuted blocks of 4 stratified within clinical centers and gestational age
groups, determined by obstetrical ultrasound (<26 or 26–28 wk 0 d), were used by the Data
Coordinating Center (DCC) for randomization. The tables were sent to the Investigational
Pharmacist at the sites. After eligibility was confirmed centrally by the project director, a
study ID number was assigned and iNO begun. A masked syringe containing either
calfactant or air was then sent to the unit and administered to the infant behind a screen by
staff not involved in providing the infant’s clinical care. Cardiorespiratory and ventilator
monitors were silenced. Control/sham infants had no procedure done behind the screen.
Based on recommendations of the investigators and institutional review boards (IRBs), it
was decided that a maximum of 5 additional doses of calfactant could be administered for
the purpose of the study starting 48 h after initial clinical treatment.
We have found that parents of multiple births who participate in a clinical study have a
strong preference that each of their children receives the same treatment. Therefore, the first

J Pediatr. Author manuscript; available in PMC 2017 January 01.

Ballard et al.

Page 5

Author Manuscript

infant in a multiple birth was randomized according to the randomization schedule and
subsequent infants were assigned to the same treatment group. This is equivalent to
randomizing the mother and is accounted for in the analysis.(26)
STUDY EFFICACY ENDPOINTS

Author Manuscript

The primary outcome was survival without BPD at 36 wk PMA (ascertained at ±1wk).
Infants discharged in room air before 36 wk were considered No BPD. Infants who required
ventilatory support and any level of supplemental oxygen, or effective fraction of inspired
oxygen (FiO2) >30% by nasal cannula (NC) were diagnosed with BPD (“severe” BPD by
the NIH workshop definition).(2) Infants receiving mechanical ventilation, NCPAP, or >4
Liters NC flow in room air were assigned Yes BPD. Infants at 36 wk receiving ≤0.3
effective FiO2 at <2 L flow or on nasal flow <4 L with room air were evaluated for their
requirement for respiratory support, determined by an oxygen/flow reduction (room air)
challenge test.(27) The secondary outcome of BPD at 40 wk was defined in the same fashion
for infants still in the hospital on support. Infants who were No BPD at 36 wk were imputed
to be No BPD at 40 wk. Infants discharged on oxygen without a challenge test were
assigned Yes BPD. The endpoints at 36 and 40 wk were determined by research staff not
involved in dosing or clinical management of the infant and were monitored by the study
project manager. Other secondary outcomes related to the severity of BPD: (1) pulmonary
outcome at 12–24 months of age; and (2) neurodevelopmental outcome at 2 y of age are still
being ascertained.
SAFETY

Author Manuscript
Author Manuscript

Known co-morbidities of prematurity including sepsis, patent ductus arteriosus (PDA),
necrotizing enterocolitis (NEC), and intraventricular hemorrhage (IVH) that might
potentially be affected by treatment were defined and tracked as potential adverse events
(AEs). Death occurring within 7 days of completion of dosing required expedited reporting
to the data safety monitoring board (DSMB) and FDA, with concurrent review by the
independent study safety monitor. Other Serious Adverse Events (SAE’s) reported at regular
intervals included severe cardiopulmonary decompensation or increase in Respiratory
Severity Score (RSS=MAPxFiO2) of >5 over baseline sustained >24 h within 4 h of a
dosing procedure, severe pulmonary hemorrhage, pneumothorax requiring a chest tube, or
significant unexpected events thought to be related to the study drug. Other adverse events
(AE) were: (1) related to study drug dosing; (2) other complications including pulmonary
hypertension or airway abnormalities; (3) complications related to tracheal aspirate
sampling; (4) requirement for CPR involving cardiac medications and chest compression; or
(5) unexpected events. Responses to the dosing procedure including transient bradycardia or
desaturation were tracked on separate, blinded dosing tolerance forms and sent directly to
the DCC.
STATISTICAL ANALYSES
The primary endpoint (survival to 36 wk without BPD) was analyzed as a dichotomous
variable and compared between treatment groups. Effect size for outcomes were analyzed by
generalized estimating equations (GEE) to account for clustering of multiple births within
one mother. Infants with missing data for the primary outcome were assumed to have BPD
J Pediatr. Author manuscript; available in PMC 2017 January 01.
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(n=2). Analyses were intention to treat: all randomized infants were included in the final
analysis. Other analyses of baseline characteristics, SAE and AE used chi square or
ANOVA without adjusting for clustering.
Two interim analyses (at 25% and 50% of completion) were planned for the DSMB
including efficacy as well as futility analyses. Stopping boundaries using an alpha spending
function resulted in a final adjusted significance level of 0.04695.(28)
To calculate power, we based incidence in the placebo group on a previous trial of iNO
therapy(11, 20) that found 44% of the infants receiving iNO alone had 36-week BPD-free
survival. We judged that a 13% absolute improvement in outcome (i.e. 44% vs. 57%) would
be clinically important and lead to a change in practice. Using a 2-sided alpha level of 0.05
and power of 0.80, we calculated a total sample size requirement of 524.

Author Manuscript

RESULTS

Author Manuscript

Patients were enrolled from January 2010, to September 2013. At the time of initiating this
study, most infants <28 wk with respiratory distress were intubated and treated with
surfactant shortly after birth and extubated to NCPAP as rapidly as tolerated. There were 17
(3%) infants who were not initially intubated at birth and 121 who were extubated and then
required re-intubation between 7 and 14 d. Infants who were still requiring intubation and
mechanical ventilation or had been re-intubated between 7–14 d (46% of those screened)
were evaluated for enrollment. The primary reasons available infants were excluded were:
congenital malformation (22), clinically unstable (112), life expectancy <7d (23), bilateral
Grade 4 IVH (33) or unlikely to be available for evaluation at 36 wk (44) (more than one
reason in 46 infants). Of the 511 (53% of eligible) infants enrolled there were 252 and 259
infants randomized to the treated and control groups, respectively (Figure; available at
www.jpeds.com). There was no difference between groups in BW (700 vs 702 grams), GA
(25.2 vs 25.2 wk), percentage <26 wk (70.6% vs 70.7%), race, sex, proportion who had
previously been extubated, severity of disease at enrollment, or co-morbidities of
prematurity at baseline (Table I). There were fewer treated infants with a sibling in the study
(17.5 treated vs 24.7% control p=0.05) and mothers of treated infants were younger (27.6 vs
29.5 years p=0.01) and had fewer years of education (p=0.05) (Table I).
OUTCOME

Author Manuscript

Survival without BPD was not different between treated vs. control groups at 36 wk (31.3%
vs. 31.7%; relative benefit 0.98 (95%CI:0.75,1.28, p=0.89) or 40 wk (58.7% vs. 54.1%;
relative benefit 1.08 (95%CI:0.92,1.27, p=0.33) (Table II). There was no difference in
severity of lung disease as indicated by days of mechanical ventilation prior to 36 wk (38.1
vs. 37.3, p=0.60), days on supplemental oxygen (69.9 vs. 69.2, p=0.65) or treatment with
systemic steroids (71.8% vs 78%, p=0.15) (Table II). There was no difference by treatment
in infants of <26 wk or 26–28 wk. All of the infants who had BPD were classified as
moderate to severe by the NIH workshop definition(2) with no difference in severity between
groups (data not shown). Unexpectedly, the non-white infants trended toward better
outcomes in both groups, with 37% versus 24% of non-white and white infants,
respectively, surviving without BPD.
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There were no differences in SAEs or co-morbidities of prematurity (AEs) occurring after
enrollment (Table III). A total of 2293 doses/sham procedures were done (Table III). Infants
were extubated as soon as possible; no infants remained intubated for the purpose of
receiving additional doses. Nevertheless, the majority of both the treated and control infants
continued to require intubation and received all 5 doses/sham procedures (78.2% and 81.9%,
respectively). The intervention was discontinued in 23 infants either at physician request or
parental withdrawal (Figure). All of the infants had episodes of transient bradycardia and
oxygen desaturation during hospitalization and required re-intubation periodically. As
expected, transient bradycardia (3.7% vs. 0.6% of procedures) and transient oxygen
desaturation (11.7% vs 4.5% of procedures) were more frequent during the dosing procedure
in the infants receiving late doses of surfactant. Fourteen treated vs 3 control infants (1.3%
vs 0.25% of dosing/sham procedures) required re-intubation during the dosing period.
Overall, the dosing procedure was well tolerated.

DISCUSSION

Author Manuscript

We found no beneficial effect of late surfactant as administered in TOLSURF on BPD-free
survival at 36 or 40 wk PMA nor on the severity of BPD as defined by an NIH Workshop.(2)
This trial of combination therapy of late doses of surfactant with iNO was designed to
address several components of the multifactorial pathobiology of BPD. In animal models of
BPD, treatment with iNO has been demonstrated to prevent increased airway resistance and
muscularity(29, 30), to transiently improve surfactant function(22), and to improve lung
growth, angiogenesis, and alveolarization(31). Clinically, iNO increased survival without
BPD and 1-year pulmonary status in one large clinical trial, (11, 20, 21) in which African
American infants tended to respond better (P=0.055 for interaction) than whites. This trial,
designed and initiated prior to the NIH consensus on the use of iNO in preterm infants, was
based on the hypothesis that the combination of iNO with late doses of surfactant, given to
address the known surfactant deficiency/dysfunction found in ventilated preterm infants
after the first week of life(13), and confirmed in a subset of TOLSURF infants prior to the
first dose, would shorten exposure to the volutrauma and oxidant stress of mechanical
ventilation, thus decreasing the severity of early lung disease and subsequent diagnosis of
BPD.

Author Manuscript

We found that the infants enrolled in this trial had a lower rate of survival without BPD at
36 wk (31%) than we had expected (44%) from our previous NO CLD study. Death before
36 wk was 5.8% in NO CLD and 7.8% in TOLSURF. We think the higher rate of BPD is
likely due to the fact that the infants in TOLSURF were 1 wk earlier mean gestational age
(25.2 vs 26 wk) with lower mean BW (700 vs 763 g) and, in addition, the infants had to be
intubated to qualify for enrollment in TOLSURF, whereas in NO CLD infants could be on
nasal CPAP at enrollment (thus TOLSURF infants had more compromised lung function
initially).
It is possible that pulmonary outcome at term (40 wk) is more predictive of childhood lung
disease secondary to prematurity than oxygen requirement at 36 wk. However, although
improved over 36 wk, survival without BPD at 40 wk was similar for treated (59%) and
J Pediatr. Author manuscript; available in PMC 2017 January 01.
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placebo (54%) infants. Treated infants did not have improved respiratory status with late
surfactant, with approximately 80% of each group continuing to require intubation despite
efforts to extubate to NCPAP or NIPPV and receiving the maximum allowed of 5 doses/
sham treatments, with no difference between groups in time to successful tracheal
extubation. If late surfactant had been effective in improving pulmonary status we would
have expected treated infants to improve with dosing and tolerate extubation sooner. We
found that late surfactant dosing was safe; in more than 2200 procedures, there were few
problems, and there was no difference in mortality or adverse events between groups.

Author Manuscript

There are several possible explanations for the failure of late doses of surfactant to improve
pulmonary outcome in this group of infants receiving iNO. The infants may not have had
enough surfactant dysfunction to benefit from replacement. This is unlikely as we found in a
subset of TOLSURF infants that levels of SP-B were low in most TA surfactants isolated
prior to dosing (data not shown), similar to findings in a previous cohort (13). There may
have been irreversible lung damage due to volutrauma, inflammation, and oxidant stress
prior to enrollment, which could not be completely addressed by iNO plus surfactant; these
infants had already received a mean of 8.6 days of mechanical ventilation and oxygen
exposure. The dose/frequency of replacement surfactant may have been inadequate.
Although we gave the standard clinical dose of calfactant, it is possible that we would have
had a better response to more frequent dosing over a longer period of time. We based our
dosing on our pilot studies in which SP-B levels in TA surfactant returned to control levels
<48 hours after calfactant instillation.(19)

Author Manuscript

Former preterm infants are at increased risk for persistent pulmonary morbidity including
asthma and wheezing disorders. (3, 10, 32, 33) Longer term, meaningful clinical outcome is
critical to understanding the value of interventions in the newborn period. In two studies of
preventative treatments, later benefit was observed despite the absence of an effect on BPD
at 36 wk PMA.(34, 35) We are following TOLSURF infants with pulmonary questionnaires
collected every 3–6 months through 24 months corrected age and assessment of
neurodevelopmental outcome at 24 months.

Author Manuscript

In conclusion, in this large randomized, masked study of late doses of surfactant combined
with iNO, there was no difference in survival without BPD at 36 wk (preterm) with both
groups demonstrating improved pulmonary outcome at 40 wk (term) PMA. Although late
surfactant treatment transiently reduces the severity of lung disease, (14–19) our findings do
not support this therapy as used in TOLSURF to prevent BPD at 36 wk. In ongoing
laboratory studies we are evaluating the response to surfactant dosing and relationship to
outcome to determine whether different timing or additional dosing might be beneficial. We
are also determining the incidence of persistent pulmonary morbidity through at least 2 years
of age to evaluate possible later risk or benefit. The observed safety of late surfactant dosing
supports its potential use as a vehicle to deliver other medications such as corticosteroids
directly to the lung.(36)
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AE

Adverse events

BPD

Bronchopulmonary dysplasia

BW

Birth weight

DCC

Data Coordinating Center

DSMB

Data Safety Monitoring Board

ELGAN

Extremely low gestational age newborn (≤28 0/7wk)

FIO2

Fraction of inspired oxygen

GA

Gestational age

GEE

Generalized estimating equations

iNO

Inhaled nitric oxide

IRB

Institutional Review Board

NC

Nasal cannula

NCPAP

Nasal continuous positive airway pressure

NHLBI

National Heart, Lung and Blood Institute

NIPPV

Nasal intermittent positive pressure ventilation

NO

Nitric Oxide

NO CLD

Inhaled Nitric Oxide to prevent Chronic Lung Disease trial

PMA

Post menstrual age

RSS

Respiratory severity score = mean airway pressure X FIO2

SAE

Serious adverse events

SP-B

Surfactant Protein B

SP-C

Surfactant Protein C

TA

Tracheal aspirate

TOLSURF

Trial of Late Surfactant
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J. Lucie, P. Conway, M.l. Sacilowski, M. Leadersdorff, P. Orbank, K. Wynn; Anne and
Robert H. Lurie Children’s Hospital/Northwestern University, Chicago, IL: M. deUngria
MD, J. Khan MD, K. Hamann, M. Schau, B. Hopkins, J. Jenson; Texas Children’s Hospital,
Houston, TX: C. Garcia; Stonybrook University Hospital, Stonybrook, NY: J. Shariff,
R.McGovern,J. Adelman, A. Combs, M. Tjersland, University of Washington, Seattle, WA:
S. Walker, E. Howland, J. Longoria, H. Meo; University of Texas Health Science Center,
Houston, TX: G. McDavid, K. Burson, R. Hinojosa, C. Johnson, K. Miller, S. Rogers, S.
Wright; University of Florida College of Medicine, Jacksonville, UF Jacksonville, and
Wolfson Children’s Hospital, Jacksonville, FL:K. Barnette, A. Kellum, M. Burke, C. Hayes,
S. Chadwick, D. Howard, C. Kennedy, R. Prince; Wake Forest School of Medicine and
Forsyth Medical Center, Winston Salem, NC: B. Stefanescu MD, J. Helderman, MD, K.
Warden, P. Brown, J. Griffin, L. Conley; University of Minnesota Children’s Hospital,
Minneapolis, MN: M. Georgieff, M.D., B. Davern, M. Mills, S. Ritter; Medical University
of South Carolina, Charleston, SC: C. Wagner, MD, D. Fanning, J. Roberson; Children’s
Hospitals and Clinics of Minnesota, St. Paul, MN: A. Lampland, MD, P. Meyers, A. Brey;
Children’s Hospitals and Clinics of Minnesota, Minneapolis, MN: C. Worwa, P. Dixon, G.
Ebert, C. Hejl, M. Maxwell, K. McCullough; University of Tennessee Health Science
Center, Memphis, TN: MT. El Abiad, MD, A. Talati, MD, S. Dempsey, K. Gammage, G.
Gower, K. James, P. LeNoue; All Children’s Hospital, St. Petersburg, FL: S. Bell, D.
Bruton, M. Beaulieu, R. Williams; Florida Hospital for Children, Orlando, FL: R. BarronNelson, S. Taylor; Arkansas Children’s Hospital and University of Arkansas Medical
Sciences, Little Rock, AK: N. C. Sikes, G. Lowe, B. Proffitt;
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Data Safety Monitoring Board – Cincinnati Children’s Hospital Medical Center, Cincinnati,
OH: A. Jobe MD, (Chair 2009–2010); UH Rainbow Babies and Children’s Hospital,
Cleveland, OH: A. Fanaroff MD (Chair 2010–2014); EMMES Corporation, Rockville, MD:
T. Clemons; Boston University School of Public Health, Boston, MA: L. Glantz; Wake
Forest School of Medicine, Winston-Salem, NC: D. Reboussin; Stanford University,
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Appendix 2. TOLSURF CLINICAL GUIDELINES 2010
24.0 APPENDIX B CLINICAL MANAGEMENT GUIDELINES
24.1 Guidelines for ventilation & oxygenation
Oxygen saturation limits (until 32 weeks’ PMA)
1.

Target saturations 85–94%

2.

Set saturation monitor limits (depending on individual center saturation targets)
a.

Lower: 80–85%

b. Upper: 92–95%
Mechanical ventilation guidelines—conventional ventilation

Author Manuscript

1.

Appropriate PEEP to maintain lung inflation. Usually 5–7 cmH2O.

2.

Tidal volume 3–7 mL/kg (usually 4–6)

3.

PCO2 target 45–70 mmHg

4.

pH target ≥ 7.15 (most want >7.20)

Suggested criteria for reintubation (until 32 weeks’ PMA)
Note: some patients, particularly if unstable or with increased work of breathing may be reintubated earlier

Author Manuscript

1.

Inability to maintain target saturation despite NCPAP > 8, nasal ventilation or high
flow nasal cannula > 3 liters per minute with FIO2 > 0.6

2.

PCO2 consistently > 70 mmHg

3.

pH consistently < 7.15

4.

Recurrent or severe (requiring bag mask ventilation) apnea despite maximal
caffeine therapy and NCPAP

24.2 Guidelines for caffeine citrate use
Caffeine citrate therapy should be considered for infants with gestational age less than 31
weeks, who are less than 10 days of age and require mechanical ventilation or CPAP, for the
following indications: apnea prophylaxis, apnea treatment, facilitation of extubation.

Author Manuscript

Recommended regimens
1.

Caffeine citrate IV/PO load 20 mg/kg/dose x1

2.

Caffeine citrate maintenance IV/PO 5–10 mg/kg/dose once daily until 32–34 weeks
post menstrual age even if infant remains intubated.

Considerations
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1.

If central apnea occurs / persists on caffeine therapy and other causes of apnea have
been ruled out, then caffeine dose may be adjusted by increasing the maintenance
dose by 1–3 mg/kg/dose (if HR < 180) to a maximum maintenance dose of 10
mg/kg/dose. In addition, one may also consider an additional caffeine bolus of
10mg/kg. When adjusting caffeine dose, give the bolus immediately regardless of
timing of the last maintenance dose. Base timing of subsequent doses from the time
the bolus is administered.

2.

Schmidt B et al. Caffeine therapy for apnea of prematurity. NEJM 2006; 354:2112–
2121.

3.

Davis PG, Schmidt B, Roberts RS, Doyle LW, Asztalos E, Haslam R, Sinha S, Tin
W; for the Caffeine for Apnea of Prematurity Trial Group. Caffeine for apnea of
prematurity trial: benefits may vary in subgroups. J Pediatr. 2009 Nov 17. [Epub
ahead of print]

24.3 Guidelines for glucocorticoids for lung disease
Potential candidates for initiation of glucocorticoids—try to avoid administration!
1.

Infants at least 2 weeks of age

2.

Other therapies optimized

3.

RSS ≥ 7 (RSS = MAP x FiO2)

4.

No contraindications to glucocorticoid therapy
a.

Indomethacin exposure within 48h

Author Manuscript

b. Systemic hypertension
c.

Active infection with < 24 hours of appropriate antibiotics

Regimen guidelines (short course)
1.

Hydrocortisone (total dose 5 mg/kg)
Day 1 – 3 mg/kg/d divided q 12h
Day 2 – 1.5 mg/kg/d divided q 12h
Day 3 – 0.5 mg/kg/d divided q 12h

2.

Dexamethasone (total dose 0.45 mg/kg = HC 6.75–9 mg/kg (15 – 20x))
Day 1 – 0.2mg/kg/d divided q12h

Author Manuscript

Day 2 – 0.15 mg/kg/d divided q12h
Day 3 – 0.1 mg/kg/d divided q12h
Regimen guidelines (long course)
Note: Discontinue or rapid taper (½ dose x 24h, ¼dose x 24h then off) if no response after
48h. Response defined as ability to wean ventilator and oxygen.
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1.

Hydrocortisone (total dose 15 mg)

Author Manuscript

Day 1–3 – 3 mg/kg/d divided q 12h
Day 4–6 – 1.5 mg/kg/d divided q 12h
Day 7–9 – 0.5 mg/kg/d divided q 12h
2.

Dexamethasone (total dose 0.89 mg/kg = HC 13.35–17.8 mg/kg (15–20x))
Day 1–3 – 0.15 mg/kg divided q 12h
Day 4–6 – 0.1 mg/kg/d divided q 12h
Day 7–8 – 0.05 mg/kg/d divided q 12h
Day 9–10 – 0.02 mg/kg/d divided q 12h

Author Manuscript

Considerations
1.

If infant requires surgery while on steroid course, consider stress dose
hydrocortisone 2–4 mg/kg/d divided q 6–12h × 24h

2.

If infant develops hypotension or other signs of adrenal insufficiency after
completion of steroid course, go back on most recent dose x 24h, then taper to ½
dose x 24h and then ¼ dose x 24h

3.

May repeat short course at 7–10d if infant meets criteria

24.4 Guidelines for glucocorticoids for hypotension
Potential candidates for initiation of glucocorticoids for hypotension

Author Manuscript

1.

Inadequate response to vasopressor therapy (dopamine ≥ 20 mcg/kg/min ±
dobutamine or epinephrine) with either
a.

persistent hypotension despite fluid resuscitation, or

b. inability to wean medications for > 48h
2.

No contraindications to glucocorticoid therapy
a.

Indomethacin exposure within 48h

b. Active infection with < 24 hours of appropriate antibiotics
Regimen guidelines
1.

Author Manuscript

Hydrocortisone (total dose 5 mg/kg). Some infants may respond to initial 1–2
doses, making further dosing unnecessary.
Day 1 – 1–2 mg/kg/d divided q 8–12h
Day 2 – 1 mg/kg/d divided q 8–12h
Day 3 – 0.5 mg/kg/d divided q 12h

Considerations
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1.

If infant requires surgery while on steroid course, consider stress dose
hydrocortisone 2–4 mg/kg/d divided q 6–12h × 24h

2.

If infant develops hypotension or other signs of adrenal insufficiency after
completion of steroid course, go back on most recent dose x 24h, then taper to ½
dose x 24h and then ¼ dose x 24h, then discontinue.

24.5 Guidelines for Vitamin A therapy (if being used)
Candidates for initiation of Vitamin A
1.

All infants < 1000 g birth weight

2.

Infants 1000–1250 g birth weight if ventilated > 24h

Dosing regimen

Author Manuscript

5000 Units IM every M, W, F x 4 weeks
May be discontinued prior to 4 weeks of treatment if infant reaches full enteral feeds
(150 mL/kg of premature formula or fortified breast milk or 120 mL/kg of premature
formula with 1 mL/d Poly-Vi-Sol)
Vitamin A use should be consistent among all infants at any site.

Author Manuscript
Author Manuscript
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Figure 1. Consort Diagram for TOLSURF showing enrollment and completion of data for the
two study groups

* Withdrawn resulted in no further treatment with either iNO or Infasurf
** One infant in each group with no data, 36 weeks outcome unknown = Yes BPD

Author Manuscript
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Table 1

Author Manuscript

Baseline Characteristics *
Characteristics of Infants

Late Surfactant

Control

252

259

Mean/SD -weeks

25.2 ± 1.2

25.2 ± 1.2

< 26 weeks no. (%)

178 (70.6)

183 (70.7)

26–28 weeks no. (%)

74 (29.4)

76 (29.3)

Mean/SD - g

700.1±173.2

702.3 ±156.0

< 750 no. (%)

163 (64.7)

162 (62.5)

≥ 750 no. (%)

89 (35.3)

97 (37.5)

≤ 10 no. (%)

49 (19.4)

39 (15.1)

> 10 no. (%)

203 (80.6)

220 (84.9)

Male sex no. (%)

143 (56.7)

138 (53.3)

N

P value

Gestational Age

Birth weight

0.70

0.88

IUGR Percentile

0.19

Author Manuscript

Mother’s Race / Ethnic Group no. (%)*

0.43
0.31

White

116 (46.0)

128 (49.4)

African American

98 (38.9)

90 (34.7)

Hispanic

23 (9.1)

33 (12.7)

15 (6)

8 (3.1)

Antenatal Corticosteroids no. (%)

216 (85.7)

224 (86.5)

0.12

Cesarean delivery no. (%)

175 (69.4)

195 (75.3)

0.14

Surfactant at birth no. (%)

251 (99.6)

258 (99.6)

1.0

no. (%)

44 (17.5)

64 (24.7)

0.05

Age at entry mean/SD - days

10.4±2.4

10.4±2.4

0.79

Other

Multiple Birth – siblings enrolled in study

Author Manuscript

Respiratory Severity Score (RSS) prior to enrollment **
Mean/SD

3.7 ± 2.3

3.8± 2.2

0.47

3.0 (2.2–4.4)

3.2 (2.3–4.8)

0.47

Conventional no. (%)

152 (60)

169 (65)

High Frequency no. (%)

99 (39)

87 (34)

10 (4.0)

9 (3.5)

0.77

Median (Interquartile range)
Vent Mode prior to enrollment no. (%)

0.20

Comorbidities prior to enrollment no. (%)***
Pneumothorax w/chest tube no. (%)

Author Manuscript

Pulmonary hemorrhage no. (%)

15 (6.0)

10 (3.9)

0.27

PDA no. (%)

85 (33.7)

94 (36.3)

0.83

PDA ligation no. (%)

8 (3.2)

6 (2.3)

0.84

NEC no. (%)

3 (1.2)

1 (0.4)

0.22

NEC/Perforation requiring surgery no. (%)

3 (1.2)

1 (0.4)

0.31

Isolated GI perforation no. (%)

13 (5.2)

7 (2.7)

0.15

Sepsis -CSF or Blood no. (%)

21(8.3)

26 (10)

0.49
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Characteristics of Infants

Late Surfactant

Control

Grade 1 or 2 no. (%)

54 (21.4)

64 (24.7)

Grade 3 or 4 no. (%)

42 (16.7)

36 (13.9)

Late Surfactant

Control

P value

27.6 ± 6.2

29.5 ± 6.6

0.001

26 (10.3)

36 (13.9)

high school +/or some college no. (%)

139 (55)

111 (43)

college graduate +/or grad school no. (%)

74 (29.4)

97 (37)

Unknown no. (%)

13 (5.2)

15 (5.8)

Intraventricular hemorrhage

Author Manuscript

Maternal Characteristics
Maternal age mean/SD years

P value
0.72

Maternal Education no. (%)

0.048

< high school no. (%)

*

Race or ethnic group was self-reported by the mother of the infant

Author Manuscript

**

The respiratory severity score was calculated as the fraction of inspired oxygen multiplied by the mean airway pressure (in centimeters of water)

***
PDA was reported only if infant had treatment with either indomethacin or Ibuprofen or surgical closure was provided. Necrotizing
enterocolitis was diagnosed by the presence of pneumatosis, hepatobiliary gas, or pneumoperitoneum on radiography, plus one or more of the
following symptoms: bilious gastric aspirate or emesis, abdominal distension, or occult blood in the stool. Sepsis was diagnosed by a positive
culture of blood or spinal fluid treated for at least 7 days.

Author Manuscript
Author Manuscript
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Table 2

Author Manuscript

Outcome to 36 and 40 weeks
Variable
N

Late Surfactant

Control

252

259

P value

0.98 (0.75, 1.28)

0.89

0.94 (0.68, 1.31)

0.72

1.06 (0.69, 1.65)

0.78

BPD at 36 weeks**
Survival without BPD no. (%)

79 (31.3)

82 (31.7)

Death or Survived with BPD no. (%)

173 (68.7)

177 (68.3)

BPD no. (%)

155 (61.5)

155 (59.8)

Died no. (%)

18 (7.1)

22 (8.5)

Gestational age < 26 weeks - n

178

183

Survival without BPD no. (%)

52 (29.2)

56 (30.6)

Death or Survived with BPD no. (%)

Author Manuscript

Relative Benefit (95%CI)*

126 (71)

127 (69.4)

BPD no. (%)

110 (61.8)

109 (59.6)

Died no. (%)

16 (9.0)

18 (9.8)

74

76

Survival without BPD no. (%)

27 (36.5)

26 (34.2)

Death or Survived with BPD no. (%)

47 (63.5)

50 (65.8)

BPD no. (%)

45 (60.8)

46 (60.5)

Died no. (%)

2 (2.7)

4 (5.3)

4

7

Discharged in room air no. (%)

3 (75.0)

2 (28.6)

Discharged on oxygen no. (%)

1 (25.0)

5 (71.4)

Gestational age 26–28 weeks – n

Respiratory Outcomes to 36weeks
Number Discharged ≤ 36 weeks

Discharged on ventilator w trach no. (%)

Author Manuscript

0

0

Days of mech ventilation mean/SD

38.1 ±18.4

37.3±16.6

0.60

Days on oxygen mean/SD

69.9 ± 16.8

69.2 ± 15.8

0.65

Treat with systemic steroids no. (%)

181 (71.8)

202 (78.0)

0.15

Survival without BPD no. (%)

148 (58.7)

140 (54.1)

Death or Survived with BPD no. (%)

BPD at 40 weeks

104 (41.2)

119 (45.9)

BPD no. (%)

83 (32.9)

96 (37.1)

Died no. (%)

21 (8.3)

23 (8.9)

Gestational age < 26 weeks - N

178

183

Survival without BPD no. (%)

102 (57.3)

97 (53.0)

Death or Survived with BPD no. (%)

76 (42.7)

86 (47.0)

BPD no. (%)

57 (32.0)

68 (37.2)

Died no. (%)

19 (10.7)

(18 (9.8))

Author Manuscript

Gestational age 26–28 weeks – N

74

76

Survival without BPD no. (%)

46 (62.2)

43 (56.6)

Death or Survived with BPD no. (%)

28 (37.8)

33 (43.4)

BPD no. (%)

26 (35.1)

28 (36.8)

Died no. (%)

2 (2.7)

5 (6.6)

1.08 (0.92,1.27)

0.33

1.08 (0.89,1.30)

0.46

1.11 (0.83,1.48)

0.47
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Variable

Late Surfactant

Control

Relative Benefit (95%CI)*

Author Manuscript

Respiratory Outcomes to 40 weeks
Number Discharged ≤ 40 weeks

85

92

Discharged in room air no. (%)

57 (67.1)

51 (55.4)

Discharged on oxygen no. (%)

28 (33.0)

41 (44.6)

*

CI denotes confidence interval

**

Primary Outcome

Author Manuscript
Author Manuscript
Author Manuscript
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Table 3

Author Manuscript

Comorbidities and dosing tolerance after entry
Late Surfactant
N
Pneumothorax with chest tube

Control

P value

252

259

2 (0.8)

2 (0.8)

0.98

Pulmonary hemorrhage

1 (0.4)

0 (0.0)

0.31

Pulmonary hypertension

25 (9.9)

28 (10.8)

0.74

PDA

89 (36.5)

95 (37.5)

0.80

PDA ligation

55 (22.5)

51 (20.2)

0.51

14 (5.6)

6 (2.3)

NEC, new/worsened

0.59

without surgery

Author Manuscript

requiring surgery

13 (5.2)

18 (6.9)

Sepsis (blood or CSF)

72 (28.6)

69 (26.6)

0.63

Tracheal stenosis

3 (1.2)

6 (2.3)

0.33

Vocal cord paralysis

4 (1.6)

5 (1.9)

0.77

16 (6.3)

23 (8.9)

Intraventricular hemorrhage, new/worsened
Grade 1 or 2
Grade 3 or 4

0.89

17 (6.7)

12 (4.6)

198 (78.6)

198 (76.4)

Surgery

34 (13.5)

29 (11.2)

0.28

Intravitreal bevacizumab

16 (6.7)

24 (9.5)

0.009

1115

1178 (sham)

ROP

0.57

Dosing Tolerance
Number of procedures
Received 5 doses no. (%)

Author Manuscript

197 (78.2)

212 (81.9)

Severe respiratory decomp** no. (%)

1 (0.4)

2 (0.8)

Reintubation ** n (% of procedures)

14 (1.3)

3 (0.3)

Bradycardia** n (% of procedures)

41 (3.7)

7 (0.6)

Desaturation** no. (%)

130 (11.7)

53 (4.5)

Pneumothorax no. (%)

1 (0.4)

1 (0.4)

24±18

24±20

Days 1st procedure to 1st extubation mean/SD

0.57

0.99

*

Dosing was not associated with pulmonary interstitial emphysema, pulmonary hemorrhage or cardiorespiratory decompensation requiring CPR

**

Findings during dosing procedure only

Author Manuscript
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